Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

116
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
116
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.3K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of home-based transcranial direct current stimulation on fatigue in multiple sclerosis.

Neurophysiologie clinique = Clinical neurophysiology·2026
Same author

Transcranial direct current stimulation (tDCS) as an additional treatment to cognitive behavior group therapy in adults with tobacco dependence - a double-blind, randomized, sham-controlled pilot trial.

Psychiatry research·2026
Same author

Reversible Acute Chorea in a Patient on Hemodialysis.

Annals of Indian Academy of Neurology·2026
Same author

Variables associated with clinical outcomes and switching from unilateral to bitemporal electroconvulsive therapy: a retrospective study.

Frontiers in psychiatry·2026
Same author

Editorial: Surgical approaches and outcomes in cervical and thoracic myelopathies.

Frontiers in surgery·2026
Same author

The effects of EXOPULSE Mollii Suit in patients with fibromyalgia: a double-blind randomized sham-controlled trial (EXOFIB2).

Pain medicine (Malden, Mass.)·2026

Related Experiment Video

Updated: Sep 2, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K

[Alexithymia in Multiple Sclerosis - Narrative Review].

Christina Grigorescu1, Moussa A Chalah2,3, Samar S Ayache2,3

  • 1Klinik für Psychiatrie und Psychotherapie, Klinikum der Universität München, München.

Fortschritte Der Neurologie-Psychiatrie
|August 10, 2022
PubMed
Summary

Alexithymia, difficulty recognizing emotions, affects 10-53% of multiple sclerosis (MS) patients. Further research is crucial for understanding its impact on MS management and patient well-being.

More Related Videos

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.8K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.1K

Related Experiment Videos

Last Updated: Sep 2, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.6K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

3.8K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.1K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Clinical Neurology

Background:

  • Alexithymia, characterized by emotional identification and expression difficulties, is prevalent in psychiatric populations.
  • Its occurrence and pathophysiology in multiple sclerosis (MS) remain under-investigated.
  • This review synthesizes current knowledge on alexithymia in MS.

Approach:

  • Narrative review of existing literature on alexithymia in multiple sclerosis.
  • Examination of prevalence, etiology, neurobiological, and clinical findings.
  • Identification of research gaps and future directions.

Key Points:

  • Prevalence of alexithymia in MS varies widely (10-53%).
  • Associations exist with anxiety, depression, fatigue, and social cognition.
  • Limited data on links with clinical/cognitive variables and pathophysiology (e.g., interhemispheric transfer, brain abnormalities).

Conclusions:

  • High prevalence suggests alexithymia significantly impacts MS patient quality of life and communication.
  • Mandatory screening for alexithymia in MS is recommended.
  • Further large-scale studies using neuroimaging are needed to elucidate neural underpinnings.